Cargando…
Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas.
RAP-5, a monoclonal antibody raised against a p21ras peptide, has been claimed to show immunohistochemical localisation of cells with infiltrative properties in human tumours. We confirmed that this antibody reveals pronounced cellular heterogeneity in human colonic neoplasms but could find no obvio...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001593/ https://www.ncbi.nlm.nih.gov/pubmed/3542007 |
_version_ | 1782135636772257792 |
---|---|
author | Robinson, A. Williams, A. R. Piris, J. Spandidos, D. A. Wyllie, A. H. |
author_facet | Robinson, A. Williams, A. R. Piris, J. Spandidos, D. A. Wyllie, A. H. |
author_sort | Robinson, A. |
collection | PubMed |
description | RAP-5, a monoclonal antibody raised against a p21ras peptide, has been claimed to show immunohistochemical localisation of cells with infiltrative properties in human tumours. We confirmed that this antibody reveals pronounced cellular heterogeneity in human colonic neoplasms but could find no obvious relationship to infiltrative activity. RAP-5 bound to many different cell types, neoplastic and normal. In order to clarify the specificities of RAP-5 we applied it to two cell lines: nontumorigenic hamster fibroblasts in which ras expression is barely detectable, and a vigorously tumorigenic line derived from these fibroblasts by insertion of the human mutated Ha-ras oncogene in a high expression vector. Another antibody to p21ras, Y13-259, clearly distinguished between these cell lines both on immunoblots and immunocytochemically, but RAP-5 did not. Rather, it bound to proteins of a variety of molecular weights in both cell lines. The results show that RAP-5 is unlikely to be a useful reagent for detection of ras associated proteins in human tissues. IMAGES: |
format | Text |
id | pubmed-2001593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1986 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20015932009-09-10 Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. Robinson, A. Williams, A. R. Piris, J. Spandidos, D. A. Wyllie, A. H. Br J Cancer Research Article RAP-5, a monoclonal antibody raised against a p21ras peptide, has been claimed to show immunohistochemical localisation of cells with infiltrative properties in human tumours. We confirmed that this antibody reveals pronounced cellular heterogeneity in human colonic neoplasms but could find no obvious relationship to infiltrative activity. RAP-5 bound to many different cell types, neoplastic and normal. In order to clarify the specificities of RAP-5 we applied it to two cell lines: nontumorigenic hamster fibroblasts in which ras expression is barely detectable, and a vigorously tumorigenic line derived from these fibroblasts by insertion of the human mutated Ha-ras oncogene in a high expression vector. Another antibody to p21ras, Y13-259, clearly distinguished between these cell lines both on immunoblots and immunocytochemically, but RAP-5 did not. Rather, it bound to proteins of a variety of molecular weights in both cell lines. The results show that RAP-5 is unlikely to be a useful reagent for detection of ras associated proteins in human tissues. IMAGES: Nature Publishing Group 1986-12 /pmc/articles/PMC2001593/ /pubmed/3542007 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Robinson, A. Williams, A. R. Piris, J. Spandidos, D. A. Wyllie, A. H. Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. |
title | Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. |
title_full | Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. |
title_fullStr | Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. |
title_full_unstemmed | Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. |
title_short | Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. |
title_sort | evaluation of a monoclonal antibody to ras peptide, rap-5, claimed to bind preferentially to cells of infiltrating carcinomas. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001593/ https://www.ncbi.nlm.nih.gov/pubmed/3542007 |
work_keys_str_mv | AT robinsona evaluationofamonoclonalantibodytoraspeptiderap5claimedtobindpreferentiallytocellsofinfiltratingcarcinomas AT williamsar evaluationofamonoclonalantibodytoraspeptiderap5claimedtobindpreferentiallytocellsofinfiltratingcarcinomas AT pirisj evaluationofamonoclonalantibodytoraspeptiderap5claimedtobindpreferentiallytocellsofinfiltratingcarcinomas AT spandidosda evaluationofamonoclonalantibodytoraspeptiderap5claimedtobindpreferentiallytocellsofinfiltratingcarcinomas AT wyllieah evaluationofamonoclonalantibodytoraspeptiderap5claimedtobindpreferentiallytocellsofinfiltratingcarcinomas |